bioRxiv Science⌕ Search

Biology subjects

Facchetti, G.

Publications and source records attributed to Facchetti, G..

2 recordsLinked to original sources

Reassessment of the basis of cell size control based on analysis of cell-to-cell variability

Fundamental mechanisms governing cell size control and homeostasis are still poorly understood. The relationship between sizes at division and birth in single cells is used as a metric to categorize the basis of size homeostasis [1-3]. Cells dividing at a fixed size regardless of birth size (sizer) are expected to show a division-birth slope of 0, whereas cells dividing after growing for a fixed size increment (adder) have an expected slope of +1 [4]. These two theoretical values are, however, rarely experimentally observed. Here we investigate possible reasons for this discrepancy. Rod-shaped fission yeast Schizosaccharomyces pombe cells divide at a fixed surface area [5, 6], and exhibit a division-birth slope of 0.23{+/-}0.04, significantly different from the sizer value of zero. To understand whether fission yeast uses a mix of sizer and adder control, or whether size sensing is simply imprecise, we developed a mathematical model of sizer control, including the relevant sources of variation. Our results support pure sizer control and show that deviation from zero slope is exaggerated by measurement of an inappropriate geometrical quantity (e.g., length instead of area), combined with cell-to-cell radius variability. The model predicts that mutants with greater errors in size sensing or septum positioning paradoxically appear to behave as better sizers. Furthermore, accounting for cell width variability, we show that pure sizer control can in some circumstances reproduce the apparent adder behaviour observed in E. coli. These findings demonstrate that refined analysis of geometric variation can lead to new insights into cell size control.

cell biology↗

Antibacterial nucleoside-analog inhibitor of bacterial RNA polymerase: pseudouridimycin

There is an urgent need for new antibacterial drugs effective against bacterial pathogens resistant to current drugs1-2. Nucleoside-analog inhibitors (NAIs) of viral nucleotide polymerases have had transformative impact in treatment of HIV3 and HCV4. NAIs of bacterial RNA polymerase (RNAP) potentially could have major impact on treatment of bacterial infection, particularly because functional constraints on substitution of RNAP nucleoside triphosphate (NTP) binding sites4-5 could limit resistance emergence4-5. Here we report the discovery, from microbial extract screening, of an NAI that inhibits bacterial RNAP and exhibits antibacterial activity against a broad spectrum of drug-sensitive and drug-resistant bacterial pathogens: pseudouridimycin (PUM). PUM is a novel microbial natural product consisting of a formamidinylated, N-hydroxylated Gly-Gln dipeptide conjugated to 6'-amino-pseudouridine. PUM potently and selectively inhibits bacterial RNAP in vitro, potently and selectively inhibits bacterial growth in culture, and potently clears infection in a mouse model of Streptococcus pyogenes peritonitis. PUM inhibits RNAP through a binding site on RNAP (the \"i+1\" NTP binding site) and mechanism (competition with UTP for occupancy of the \"i+1\" NTP binding site) that differ from those of the RNAP inhibitor and current antibacterial drug rifampin (Rif). PUM exhibits additive antibacterial activity when co-administered with Rif, exhibits no cross-resistance with Rif, and exhibits a spontaneous resistance rate an order-of-magnitude lower than that of Rif. The results provide the first example of a selective NAI of bacterial RNAP, provide an advanced lead compound for antibacterial drug development, and provide structural information and synthetic routes that enable lead optimization for antibacterial drug development.

molecular biology↗